Enlivex Therapeutics
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2005-10-01
- Employees
- 49
- Market Cap
- -
- Website
- http://www.enlivex.com
- Introduction
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT06522035
- Locations
- 🇮🇱
Carmel Medical Center, Haifa, Israel
🇮🇱Meir Medical Center, Kfar Saba, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
Study of Intra-articular Allocetra in Knee Osteoarthritis
- Conditions
- Osteoarthritis, Knee
- Interventions
- Other: Placebo
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT06233474
- Locations
- 🇩🇰
Sanos Clinic Herlev, Herlev, Denmark
🇩🇰Sanos Clinic Syddanmark, Vejle, Denmark
🇮🇱Hasharon Medical Center, Petach Tikva, Israel
A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04922957
- Locations
- 🇮🇱
Hadassah Ein Kerem Medical Center, Jerusalem, Israel
Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04659304
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
- Conditions
- Community-acquired PneumoniaSepsisCholecystitis, AcuteUrinary Tract InfectionsCholangitis AcuteIntraabdominal Infections
- Interventions
- Other: Placebo
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT04612413
- Locations
- 🇳🇱
Radboud UMC, Nijmegen, Netherlands
🇧🇪CHU de Charleroi, Charleroi, Belgium
🇧🇪Ziekenhuis Oost-Limburg, Genk, Belgium
Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS
- Conditions
- Organ Dysfunction Syndrome Sepsis
- Interventions
- Biological: Allocetra-OTS
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Enlivex Therapeutics Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03925857
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel